Head of the Leukemias Treatment Unit and « Translational Medicine in Hematology » Team at IPC | Co-director of the « Evaluation of Therapeutic Oncology and Hematology » unit at IPC | Professor in hematology at Aix-Marseille University
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
MI and YOU
Show your commitment to MI - Share your experienceClick here